ES2623464T3 - Nuevo factor de viabilidad neuronal y su uso para tratar la distrofia de conos - Google Patents
Nuevo factor de viabilidad neuronal y su uso para tratar la distrofia de conos Download PDFInfo
- Publication number
- ES2623464T3 ES2623464T3 ES08760606.7T ES08760606T ES2623464T3 ES 2623464 T3 ES2623464 T3 ES 2623464T3 ES 08760606 T ES08760606 T ES 08760606T ES 2623464 T3 ES2623464 T3 ES 2623464T3
- Authority
- ES
- Spain
- Prior art keywords
- rdcvf
- rdcvf2
- treat
- exon
- neuronal viability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000035899 viability Effects 0.000 title description 2
- 230000001537 neural effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 101000597433 Mus musculus Nucleoredoxin-like protein 1 Proteins 0.000 description 19
- 101710106007 Nucleoredoxin-like protein 2 Proteins 0.000 description 11
- 102100036205 Nucleoredoxin-like protein 2 Human genes 0.000 description 9
- 108020005038 Terminator Codon Proteins 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 description 3
- 102100036407 Thioredoxin Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101000594757 Mus musculus Nucleoredoxin-like protein 2 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241001441722 Takifugu rubripes Species 0.000 description 1
- 241000422914 Tetraodon nigroviridis Species 0.000 description 1
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
- 101710159478 Thioredoxin-like protein Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07109652 | 2007-06-05 | ||
| EP07109652A EP2027889A1 (en) | 2007-06-05 | 2007-06-05 | New neuronal viability factor and use thereof |
| PCT/EP2008/057031 WO2008148860A1 (en) | 2007-06-05 | 2008-06-05 | New neuronal viability factor and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2623464T3 true ES2623464T3 (es) | 2017-07-11 |
Family
ID=38573348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08760606.7T Active ES2623464T3 (es) | 2007-06-05 | 2008-06-05 | Nuevo factor de viabilidad neuronal y su uso para tratar la distrofia de conos |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9575075B2 (enExample) |
| EP (2) | EP2027889A1 (enExample) |
| JP (1) | JP5671678B2 (enExample) |
| ES (1) | ES2623464T3 (enExample) |
| WO (1) | WO2008148860A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1625210E (pt) | 2003-05-21 | 2011-03-15 | Genzyme Corp | Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios |
| EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
| EP2281047B1 (en) | 2008-04-15 | 2020-04-08 | Genzyme Corporation | Methods to produce rod-derived cone viability factor (rdcvf) |
| EP2383286A1 (en) | 2010-04-30 | 2011-11-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of retinal degenerative diseases |
| WO2013063383A2 (en) | 2011-10-27 | 2013-05-02 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
| US9265786B1 (en) * | 2012-03-30 | 2016-02-23 | University Of Wyoming | Method for reducing protein misfolding and accumulation in Huntington'S disease cells |
| WO2016185242A1 (en) | 2015-05-21 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Synergistic combination of neuronal viability factors and uses thereof |
| US10946063B2 (en) | 2016-10-11 | 2021-03-16 | Welltat Ophthalmics Corporation | Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide |
| WO2018134168A1 (en) | 2017-01-17 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
| WO2019077159A1 (en) | 2017-10-20 | 2019-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR |
| SG11202006796RA (en) | 2017-12-22 | 2020-08-28 | Sparingvision | Constructs comprising neuronal viability factors and uses thereof |
| EP4326339B1 (en) | 2021-04-20 | 2025-04-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Compositions and methods for treating retinal degenerative disorders |
| EP4366757A1 (en) * | 2021-07-07 | 2024-05-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies |
| AU2023362592A1 (en) | 2022-10-20 | 2025-05-08 | Centre National De La Recherche Scientifique | Compositions and methods for treating retinal degenerative disorders |
| WO2024206928A1 (en) | 2023-03-30 | 2024-10-03 | Pharma Cinq, Llc | VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2402563A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| FR2823221B1 (fr) * | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| FR2870241B1 (fr) * | 2004-05-13 | 2015-02-27 | Novartis Ag | Facteur de viabilite des cones derive des batonnets ou rdcvf et applications |
| US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
| JP5710265B2 (ja) * | 2007-12-06 | 2015-04-30 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 網膜変性疾患の治療のための栄養因子 |
| WO2010029130A1 (en) * | 2008-09-10 | 2010-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neuronal viability factor and use thereof |
| WO2013063383A2 (en) * | 2011-10-27 | 2013-05-02 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
| WO2016185242A1 (en) * | 2015-05-21 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Synergistic combination of neuronal viability factors and uses thereof |
| WO2019077159A1 (en) * | 2017-10-20 | 2019-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR |
| SG11202006796RA (en) * | 2017-12-22 | 2020-08-28 | Sparingvision | Constructs comprising neuronal viability factors and uses thereof |
-
2007
- 2007-06-05 EP EP07109652A patent/EP2027889A1/en not_active Withdrawn
-
2008
- 2008-06-05 JP JP2010510812A patent/JP5671678B2/ja active Active
- 2008-06-05 WO PCT/EP2008/057031 patent/WO2008148860A1/en not_active Ceased
- 2008-06-05 ES ES08760606.7T patent/ES2623464T3/es active Active
- 2008-06-05 US US12/602,736 patent/US9575075B2/en active Active
- 2008-06-05 EP EP08760606.7A patent/EP2175932B1/en active Active
-
2016
- 2016-07-08 US US15/205,797 patent/US20170014478A1/en not_active Abandoned
-
2018
- 2018-10-02 US US16/149,420 patent/US20190064189A1/en not_active Abandoned
-
2019
- 2019-12-12 US US16/711,492 patent/US11428698B2/en active Active
-
2022
- 2022-07-18 US US17/866,900 patent/US20220404376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5671678B2 (ja) | 2015-02-18 |
| US20190064189A1 (en) | 2019-02-28 |
| US20200174023A1 (en) | 2020-06-04 |
| US11428698B2 (en) | 2022-08-30 |
| US20100247496A1 (en) | 2010-09-30 |
| US20220404376A1 (en) | 2022-12-22 |
| US20170014478A1 (en) | 2017-01-19 |
| EP2175932B1 (en) | 2017-01-25 |
| EP2027889A1 (en) | 2009-02-25 |
| US9575075B2 (en) | 2017-02-21 |
| WO2008148860A1 (en) | 2008-12-11 |
| EP2175932A1 (en) | 2010-04-21 |
| JP2010529958A (ja) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2623464T3 (es) | Nuevo factor de viabilidad neuronal y su uso para tratar la distrofia de conos | |
| Chakraborty et al. | Evolution of genome structure in the Drosophila simulans species complex | |
| ES2670531T3 (es) | Un método para producir una escisión de ADN precisa utilizando la actividad nickasa de Cas9 | |
| AU2023278107A1 (en) | 3' UTR sequences for stabilization of RNA | |
| TWI747808B (zh) | 新穎之ｃｈｏ整合位點及其用途 | |
| ES2887852T3 (es) | Animales con IL-4 e IL-4R alfa humanizadas | |
| RU2457250C2 (ru) | Способы и композиции для экспрессии антисмысловой вирусной рнк в клетках собаки | |
| ES2877275T3 (es) | Animales con dipeptidil peptidasa IV (DPP4) humanizada | |
| KR102151065B1 (ko) | 동물 배아의 염기 교정용 조성물 및 염기 교정 방법 | |
| Schurko et al. | Meiosis genes in Daphnia pulex and the role of parthenogenesis in genome evolution | |
| PT1979474E (pt) | Transcriptase inversa da telomerase aviária | |
| WO2021011929A1 (en) | Use of frataxin for treating leigh syndrome, french canadian type | |
| Bucher et al. | Occurrence of oligopurine. oligopyrimidine tracts in eukaryotic and prokaryotic genes | |
| CN111100877B (zh) | 肥厚型心肌病小鼠模型的制备方法及其应用 | |
| CN111718933A (zh) | 一种rrbp1基因敲除热带爪蛙模型的制备方法与应用 | |
| Tao et al. | The cloning of Dmc1 cDNAs and a comparative study of its expression in different ploidy cyprinid fishes | |
| WO2022148253A1 (zh) | 一种人klf7基因启动子及其构建方法与应用 | |
| Burgoyne et al. | The roles of mouse Y chromosome genes in spermatogenesis | |
| Rentsendorj et al. | A genomic imprinting defect in mice traced to a single gene | |
| JP7055469B2 (ja) | ホモ接合型細胞の作製方法 | |
| Shimoda et al. | Imprinting of a small nucleolar RNA gene on mouse chromosome 12 | |
| Street et al. | A DNA variant within the MYO7A promoter regulates YY1 transcription factor binding and gene expression serving as a potential dominant DFNA11 auditory genetic modifier | |
| Daish et al. | Location, location, location! Monotremes provide unique insights into the evolution of sex chromosome silencing in mammals | |
| US20240373829A1 (en) | Genetic resistance to viral disease in salmonid fish | |
| ES2732100T3 (es) | Composiciones y métodos para el tratamiento de trastornos por expansión de repeticiones de nucleótidos |